Lipocine Inc.
LPCNLipocine Inc. (LPCN) is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for metabolic and other medical conditions. The company’s pipeline includes oral testosterone therapies and other products designed to improve patient compliance and outcomes. Lipocine aims to leverage its expertise in drug delivery technology to address unmet medical needs.
Company News
Lipocine announced 80% enrollment completion in its Phase 3 clinical trial for LPCN 1154, an oral brexanolone treatment for postpartum depression. The study is on track for topline results in Q2 2026, with 66 of 80 planned participants randomized.
Lipocine Inc. announced it will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, showcasing its proprietary oral drug delivery technology and clinical development candidates.
The sarcopenia market remains largely untapped, with significant unmet medical needs and no approved drug therapies. However, pharmaceutical interest is rising, particularly around muscle-enhancing agents and anti-inflammatory pathways. Regulatory bodies are beginning to recognize sarcopenia as a distinct clinical condition, which may streamline ...
Lipozem, a turmeric-based supplement, claims to address the root cause of stubborn weight gain - inflammation within fat cells. Consumer reports highlight remarkable weight loss results, with some users losing over 90 lbs in just 3 months. The supplement's unique formula, developed by Dr. Julian Ross, targets inflammation directly, enabling natur...
The report provides an in-depth analysis of the Postpartum Depression (PPD) pipeline, showcasing insights into more than ten diverse companies and over ten pipeline drugs. It highlights innovative therapeutic candidates, including RE-104 by Reunion Neuroscience and GH001 by GH Research, and their potential impact on PPD treatment paradigms.
